Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm Biopharmaceuticals Limited's (ASX:PAR) future prospects. Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. With the latest financial year loss of AU$19m and a trailing-twelve-month loss of AU$36m, the AU$113m market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Paradigm Biopharmaceuticals' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Paradigm Biopharmaceuticals is bordering on breakeven, according to the 2 Australian Biotechs analysts. They anticipate the company to incur a final loss in 2027, before generating positive profits of AU$100m in 2028. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 92%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Given this is a high-level overview, we won’t go into details of Paradigm Biopharmaceuticals' upcoming projects, but, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

View our latest analysis for Paradigm Biopharmaceuticals

Before we wrap up, there’s one issue worth mentioning. Paradigm Biopharmaceuticals currently has a debt-to-equity ratio of 147%. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, and the company has considerably exceeded this. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.

Next Steps:

There are too many aspects of Paradigm Biopharmaceuticals to cover in one brief article, but the key fundamentals for the company can all be found in one place – Paradigm Biopharmaceuticals' company page on Simply Wall St. We've also put together a list of pertinent factors you should look at:

1. Valuation: What is Paradigm Biopharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Paradigm Biopharmaceuticals is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Paradigm Biopharmaceuticals’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.